<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Brief Bioinform</journal-id>
    <journal-id journal-id-type="iso-abbrev">Brief Bioinform</journal-id>
    <journal-id journal-id-type="publisher-id">bib</journal-id>
    <journal-title-group>
      <journal-title>Briefings in Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1467-5463</issn>
    <issn pub-type="epub">1477-4054</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9116376</article-id>
    <article-id pub-id-type="pmid">35368077</article-id>
    <article-id pub-id-type="doi">10.1093/bib/bbac090</article-id>
    <article-id pub-id-type="publisher-id">bbac090</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Problem Solving Protocol</subject>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>cSurvival: a web resource for biomarker interactions in cancer outcomes and in cell lines</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Cheng</surname>
          <given-names>Xuanjin</given-names>
        </name>
        <!--jcheng@cmmt.ubc.ca-->
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="aff3" ref-type="aff">3</xref>
        <xref rid="cor1" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Yongxing</given-names>
        </name>
        <!--yongxingliu0820@gmail.com-->
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="aff3" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Jiahe</given-names>
        </name>
        <!--richmondjonas@gmail.com-->
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="aff3" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Yujie</given-names>
        </name>
        <!--yujiech2000@gmail.com-->
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="aff3" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Robertson</surname>
          <given-names>Andrew Gordon</given-names>
        </name>
        <!--grobertson@bcgsc.ca-->
        <xref rid="aff4" ref-type="aff">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4728-2343</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Xuekui</given-names>
        </name>
        <!--xuekui@uvic.ca-->
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Jones</surname>
          <given-names>Steven J M</given-names>
        </name>
        <!--sjones@bcgsc.ca-->
        <xref rid="aff3" ref-type="aff">3</xref>
        <xref rid="aff4" ref-type="aff">4</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2432-7257</contrib-id>
        <name>
          <surname>Taubert</surname>
          <given-names>Stefan</given-names>
        </name>
        <!--taubert@cmmt.ubc.ca-->
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="aff3" ref-type="aff">3</xref>
        <xref rid="cor1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><label>1</label><institution>Centre for Molecular Medicine and Therapeutics, The University of British Columbia</institution>, Vancouver, British Columbia, <country country="CA">Canada</country></aff>
    <aff id="aff2"><label>2</label><institution>British Columbia Children’s Hospital Research Institute</institution>, Vancouver, British Columbia, <country country="CA">Canada</country></aff>
    <aff id="aff3"><label>3</label><institution>Department of Medical Genetics, The University of British Columbia</institution>, Vancouver, British Columbia, <country country="CA">Canada</country></aff>
    <aff id="aff4"><label>4</label><institution>Canada’s Michael Smith Genome Sciences Centre at BC Cancer Agency</institution>, Vancouver, British Columbia, <country country="CA">Canada</country></aff>
    <aff id="aff5"><label>5</label><institution>Department of Mathematics and Statistics, University of Victoria</institution>, Victoria, British Columbia, <country country="CA">Canada</country></aff>
    <author-notes>
      <corresp id="cor1">Corresponding authors: Xuanjin Cheng, Centre for Molecular Medicine and Therapeutics; British Columbia Children's Hospital Research Institute; Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, V5Z 4H4, Canada. Tel.: +1-604-875-3860; Fax: +1 604-875-3819; E-mail: <email>jcheng@cmmt.ubc.ca</email>; Stefan Taubert, Centre for Molecular Medicine and Therapeutics; British Columbia Children's Hospital Research Institute; Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, V5Z 4H4, Canada. Tel.: +1-604-875-3860; Fax: +1 604-875-3819; E-mail: <email>taubert@cmmt.ubc.ca</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>5</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-04-02">
      <day>02</day>
      <month>4</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>02</day>
      <month>4</month>
      <year>2022</year>
    </pub-date>
    <volume>23</volume>
    <issue>3</issue>
    <elocation-id>bbac090</elocation-id>
    <history>
      <date date-type="received">
        <day>5</day>
        <month>10</month>
        <year>2021</year>
      </date>
      <date date-type="rev-recd">
        <day>2</day>
        <month>2</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>24</day>
        <month>2</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="bbac090.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Survival analysis is a technique for identifying prognostic biomarkers and genetic vulnerabilities in cancer studies. Large-scale consortium-based projects have profiled &gt;11 000 adult and &gt;4000 pediatric tumor cases with clinical outcomes and multiomics approaches. This provides a resource for investigating molecular-level cancer etiologies using clinical correlations. Although cancers often arise from multiple genetic vulnerabilities and have deregulated gene sets (GSs), existing survival analysis protocols can report only on individual genes. Additionally, there is no systematic method to connect clinical outcomes with experimental (cell line) data. To address these gaps, we developed cSurvival (<ext-link xlink:href="https://tau.cmmt.ubc.ca/cSurvival" ext-link-type="uri">https://tau.cmmt.ubc.ca/cSurvival</ext-link>). cSurvival provides a user-adjustable analytical pipeline with a curated, integrated database and offers three main advances: (i) joint analysis with two genomic predictors to identify interacting biomarkers, including new algorithms to identify optimal cutoffs for two continuous predictors; (ii) survival analysis not only at the gene, but also the GS level; and (iii) integration of clinical and experimental cell line studies to generate synergistic biological insights. To demonstrate these advances, we report three case studies. We confirmed findings of autophagy-dependent survival in colorectal cancers and of synergistic negative effects between high expression of <italic toggle="yes">SLC7A11</italic> and <italic toggle="yes">SLC2A1</italic> on outcomes in several cancers. We further used cSurvival to identify high expression of the Nrf2-antioxidant response element pathway as a main indicator for lung cancer prognosis and for cellular resistance to oxidative stress-inducing drugs. Altogether, these analyses demonstrate cSurvival’s ability to support biomarker prognosis and interaction analysis via gene- and GS-level approaches and to integrate clinical and experimental biomedical studies.</p>
    </abstract>
    <kwd-group>
      <kwd>genetic interaction</kwd>
      <kwd>survival analysis</kwd>
      <kwd>TCGA</kwd>
      <kwd>TARGET</kwd>
      <kwd>DepMap</kwd>
      <kwd>biomarker</kwd>
    </kwd-group>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Canadian Institutes of Health Research</institution>
            <institution-id institution-id-type="DOI">10.13039/501100000024</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>PJT-153199</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Natural Sciences and Engineering Research Council of Canada</institution>
            <institution-id institution-id-type="DOI">10.13039/501100000038</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>RGPIN-2018-05133</award-id>
        <award-id>RGPIN-2017-04722</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Canada Research Chair</institution>
          </institution-wrap>
        </funding-source>
        <award-id>950231363</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Canada Research Chairs Program</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Canadian Institutes of Health Research</institution>
            <institution-id institution-id-type="DOI">10.13039/501100000024</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>PJT-153199</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="12"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec id="sec3">
    <title>Introduction</title>
    <p>Survival analysis, or, more broadly, time-to-event analysis, assesses the statistical association between potential risk factors and the time to an event such as death or disease recurrence [<xref rid="ref1" ref-type="bibr">1</xref>, <xref rid="ref2" ref-type="bibr">2</xref>]. In both basic and clinical cancer biology studies, survival analysis is an important technique for identifying prognostic biomarkers and genetic vulnerabilities. Experimentally, it is useful for hypothesis generation and mechanistic inference. Clinically, it may help stratify patients into subgroups with distinct risk profiles and guide therapeutic decisions [<xref rid="ref3" ref-type="bibr">3</xref>, <xref rid="ref4" ref-type="bibr">4</xref>].</p>
    <p>Since 2006, consortium-based projects, such as The Cancer Genome Atlas (TCGA) and the Therapeutically Applicable Research to Generate Effective Treatments (TARGET), have gathered clinicopathologic data along with multiomics molecular profiles of more than 15 000 adult and pediatric human tumors across diverse cancer types [<xref rid="ref5" ref-type="bibr">5–7</xref>]. Such large data resources allow exploration into cancers at the molecular level, using clinical correlations at an unprecedented scale [<xref rid="ref6" ref-type="bibr">6</xref>].</p>
    <p>Despite the importance of survival analysis and the richness of tumor molecular datasets, we find that currently available tools do not fully exploit the potential of survival analysis (<xref rid="sup2" ref-type="supplementary-material">Supplementary Table 1</xref>, see Supplementary Data available online at <italic toggle="yes">Briefings in Bioinformatics</italic> online). First, existing tools can only analyze one genomic predictor at a time, typically mutation or expression of an individual gene [<xref rid="ref8" ref-type="bibr">8–24</xref>]. However, cancer often occurs due to multiple (epi)genomic alterations, creating highly connected molecular networks where different alterations synergize to cause malignancy. Cross talk can happen between different factors in cancers, for example microRNA (miRNA) expression and deoxyribonucleic acid (DNA) methylation [<xref rid="ref25" ref-type="bibr">25</xref>]. In survival analysis, incorporating more than one predictor could identify interactions between molecular alterations. Such interaction analysis could also be used to screen for synthetic lethality or to identify compensatory targets for nontargetable drivers [<xref rid="ref26" ref-type="bibr">26–29</xref>]. This, in turn, could facilitate the development of combination therapies (e.g. drug cocktails), which have higher efficacy and milder adverse effects than monotherapies (aka one-gene-one-drug) approaches [<xref rid="ref30" ref-type="bibr">30</xref>, <xref rid="ref31" ref-type="bibr">31</xref>]. Second, existing tools support analysis only at the single-gene level [<xref rid="ref8" ref-type="bibr">8–24</xref>]; however, molecular dysregulations in cancers may involve GSs [<xref rid="ref32" ref-type="bibr">32</xref>], in which a collection of genes act in concert. For example, a GS may represent a specific pathway (e.g. transforming growth factor-β-mediated SMAD signaling), biological process (e.g. cell cycle), disease (e.g. hereditary nonpolyposis colorectal cancer) or treatment (e.g. chemotherapy) [<xref rid="ref33" ref-type="bibr">33</xref>, <xref rid="ref34" ref-type="bibr">34</xref>]. Given this, analysis of prognostic biomarkers at the GS level rather than at the single-gene level should be informative [<xref rid="ref35" ref-type="bibr">35–37</xref>]. Third, experimentally derived cancer cell line viability data [<xref rid="ref38" ref-type="bibr">38–40</xref>] and multiomics profiling [<xref rid="ref41" ref-type="bibr">41</xref>] provide valuable <italic toggle="yes">in vitro</italic> information on genetic dependencies and interactions; however, no existing tool connects clinical data to such experimental studies. This hinders identifying suitable preclinical cell line tools to investigate molecular mechanisms underpinning poor prognosis.</p>
    <p>Motivated by the lack of suitable tools to address the above challenges, we developed cSurvival (<xref rid="f2" ref-type="fig">Figure 1</xref>). Its major advances are as follows.</p>
    <fig position="float" id="f2">
      <label>Figure 1</label>
      <caption>
        <p>Overview of the cSurvival analytical framework. DepMap, Dependency Map; eVITTA, easy Visualization and Inference Toolbox for Transcriptome Analysis; Cat., categorical predictor; Cont., continuous predictor; Mut, mutated; HR, hazard ratio; <italic toggle="yes">P</italic>, <italic toggle="yes">P</italic>-value; <italic toggle="yes">P</italic>.adj, adjusted <italic toggle="yes">P</italic>-value; Cor, correlation coefficient.</p>
      </caption>
      <graphic xlink:href="bbac090f1" position="float"/>
    </fig>
    <p>(i) Joint analysis with two genomic predictors on a wide range of individual cancer types or combinations of cancer types, including new algorithms to search for optimal cutoffs in combinations of two continuous predictors, in order to stratify patients into risk groups. The two predictors can include combinations of diverse data types that can include gene or GS expression, somatic mutation, miRNA expression, DNA methylation and protein expression.</p>
    <p>(ii) Survival analysis at the GS level with comprehensive and up-to-date GS libraries from the easy Visualization and Inference Toolbox for Transcriptome Analysis (eVITTA) project, a webserver dedicated to analyzing, comparing and visualizing transcriptome patterns [<xref rid="ref42" ref-type="bibr">42</xref>].</p>
    <p>(iii) A pipeline to integrate clinical outcomes and experimental cancer cell line data.</p>
    <p>We have combined a curated cancer outcomes database with a refined analytical pipeline and customizable visualizations into the cSurvival webserver so that nonprogrammers can use it. In the work described here, we demonstrate cSurvival’s capabilities with three case studies and more application cases in our user guide (<ext-link xlink:href="https://tau.cmmt.ubc.ca/cSurvival/help.html#9_Application_cases" ext-link-type="uri">https://tau.cmmt.ubc.ca/cSurvival/help.html#9_Application_cases</ext-link>). We not only recapitulated reported cancer biomarkers and their interactions but also identified genetic regulations consistent with published studies, demonstrating that cSurvival’s advanced pipeline facilitates cancer biomarker studies.</p>
  </sec>
  <sec id="sec4">
    <title>Materials and methods</title>
    <sec id="sec5">
      <title>Data extraction and processing</title>
      <sec id="sec6">
        <title>The Cancer Genome Atlas</title>
        <p>We extracted curated clinical outcome endpoints data from the TCGA Pan-Cancer Clinical Data Resource [<xref rid="ref6" ref-type="bibr">6</xref>] and multiomics molecular data from [<xref rid="ref43" ref-type="bibr">43</xref>]. We removed 2614 low-quality samples (Do_not_use = True) and flagged additional 507 problematic cases based on comments in the merged_sample_quality_annotations.tsv file (<ext-link xlink:href="https://gdc.cancer.gov/node/977" ext-link-type="uri">https://gdc.cancer.gov/node/977</ext-link>). While cSurvival removes these 507 cases (<ext-link xlink:href="https://tau.cmmt.ubc.ca/cSurvival/project_data/977/flagged_cases.tsv" ext-link-type="uri">https://tau.cmmt.ubc.ca/cSurvival/project_data/977/flagged_cases.tsv</ext-link>) by default, a user can choose to include them via the web interface. Next, we used TCGA sample type codes (<ext-link xlink:href="https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/sample-type-codes" ext-link-type="uri">https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/sample-type-codes</ext-link>) to extract tumor samples: for solid tumors, we extracted primary solid tumor (01) samples; for acute myeloid leukemia, we extracted primary blood-derived tumors (03 and 09); for skin cutaneous melanoma, we extracted both primary solid (01) and metastatic tumors (06). Then, from Ref. [<xref rid="ref43" ref-type="bibr">43</xref>], we used batch-corrected, upper quartile-normalized RNA-Seq by Expectation Maximization (RSEM) data; merged somatic mutation calls from the Multi-Center Mutation Calling in Multiple Cancers project [<xref rid="ref44" ref-type="bibr">44</xref>]; purity- and ploidy-corrected, gene-level, thresholded somatic copy number (CN) data; batch-corrected, reads per million data for expressed miRNA mature strands; beta values from Illumina HumanMethylation27 (HM27) and HumanMethylation450 (HM450) arrays; and batch-corrected reverse-phase protein array (RPPA) data. For duplicated tumor samples, for gene expression, miRNA expression, DNA methylation and RPPA data, we calculated the geometric means as the final readouts. Statistics in log scale are commonly used to summarize the characteristics of genomic data, since their original values are usually not normally distributed (such as log-fold changes reported by Model-based Analysis of Single-cell Transcriptomics (MAST) [<xref rid="ref45" ref-type="bibr">45</xref>] and edgeR [<xref rid="ref46" ref-type="bibr">46</xref>] in differential expression analysis). Hence, we use the geometric mean to represent the average, which is equivalent to the exponential of the average of log-transformed data. We further used the annotations in [<xref rid="ref47" ref-type="bibr">47</xref>] to map HM27 and HM450 probe IDs with chromosomal coordinates and adjacent genes.</p>
      </sec>
      <sec id="sec7">
        <title>Therapeutically Applicable Research to Generate Effective Treatment</title>
        <p>We extracted clinical and multiomics data from the NCI Genomic Data Commons (GDC) [<xref rid="ref48" ref-type="bibr">48</xref>] (<ext-link xlink:href="https://gdc.cancer.gov/" ext-link-type="uri">https://gdc.cancer.gov/</ext-link>) with TCGAbiolinks v2.16.4 [<xref rid="ref49" ref-type="bibr">49–51</xref>]. As above, we extracted primary tumor samples (01 for solid tumors, 03 and 09 for blood-derived). We used Fragments Per Kilobase of transcript per Million mapped reads upper quartile (FPKM-UQ) data for gene expression analysis, and open-access somatic mutation calls for mutation analysis. We converted Ensembl gene IDs into Human Genome Organisation (HUGO) symbols and Entrez IDs using <ext-link xlink:href="http://org.Hs.eg" ext-link-type="uri">org.Hs.eg</ext-link>.db v3.11.4 [<xref rid="ref52" ref-type="bibr">52</xref>].</p>
      </sec>
      <sec id="sec8">
        <title>Dependency Map</title>
        <p>We extracted cell line annotation, mutation, gene exp-ression (transcripts per million [TPM]), CN, clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, RNA interference (RNAi) and drug sensitivity data from Dependency Map (DepMap) 21Q3 [<xref rid="ref39" ref-type="bibr">39–41</xref>, <xref rid="ref53" ref-type="bibr">53</xref>], normalized protein expression levels from the CCLE proteomics (TS2) database (accessed on 5/19/2021) [<xref rid="ref54" ref-type="bibr">54</xref>] and drug information from the Drug Repurposing Hub v3/24/2020 [<xref rid="ref55" ref-type="bibr">55</xref>].</p>
      </sec>
    </sec>
    <sec id="sec9">
      <title>Calculating GS expression</title>
      <p>After a user selects a cancer type or combinations of cancer types, we first transform the normalized gene expression values (upper quartile-normalized RSEM in TCGA, FPKM-UQ in TARGET, TPM in DepMap) of all samples in the selected cancer type(s) into z-scores. Specifically, for a given gene, its <italic toggle="yes">z</italic>-score in a sample (patient in TCGA and TARGET, cell line in DepMap) is calculated as <inline-formula><tex-math notation="LaTeX" id="ineq01">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$z=\frac{(x-\mu )}{\sigma }$\end{document}</tex-math></inline-formula>, where <inline-formula><tex-math notation="LaTeX" id="ineq02">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$x$\end{document}</tex-math></inline-formula> is the expression value of the gene in the sample, <inline-formula><tex-math notation="LaTeX" id="ineq03">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mu$\end{document}</tex-math></inline-formula> is the mean count of the gene across samples and σ is the standard deviation of all expression values of the gene across samples. Then, for each sample, we computed the expression of a GS as the average expression <italic toggle="yes">z</italic>-score of all genes within the GS [<xref rid="ref36" ref-type="bibr">36</xref>].</p>
    </sec>
    <sec id="sec10">
      <title>Survival analysis</title>
      <sec id="sec11">
        <title>Censoring</title>
        <p>A user chooses a censoring time in days, months (30.4375 days) or years (365.25 days) (default: 10 years). For a selected clinical endpoint [e.g. overall survival (OS), progression-free survival], if the time-to-event is larger than the defined time, we set censoring status to 0 and time to the defined time; if the time-to-event is smaller than or equal to the defined time, we set censoring status to 1 and time stays unchanged.</p>
      </sec>
      <sec id="sec12">
        <title>Survival analysis</title>
        <p>We apply Kaplan–Meier (KM) log-rank tests (default) and Cox proportional-hazards (PH) regression models to assess the association with prognosis, using survival v3.2.11 [<xref rid="ref56" ref-type="bibr">56</xref>]. In joint analysis with two predictors, we use the KM log-rank test (default) or Cox PH likelihood ratio test to assess the overall significance of any difference between the four subgroup combinations of two predictors (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 1</xref>, see Supplementary Data available online at <italic toggle="yes">Briefings in Bioinformatics</italic> online). In addition, we apply Cox PH regression models to assess how two predictors jointly impact outcomes by calculating the effect sizes (hazard ratios, HRs) and the statistical significances of the two predictors and their interaction, from the fitted regression model. Alternatively, users select a risk subgroup of interest, and we then apply a KM log-rank test (default) or Cox PH likelihood ratio test to assess the difference between the selected subgroup and the rest of the cases.</p>
      </sec>
      <sec id="sec13">
        <title>Determining optimal cutoffs for continuous predictors</title>
        <p>By default, for analysis with a single continuous predictor (gene expression, miRNA expression, DNA methylation, protein expression and cell line unthresholded CN), and for joint analysis with combinations of continuous and categorical predictors, we determine optimal cutoffs using the minimum <italic toggle="yes">P</italic>-value (default: KM log-rank) method [<xref rid="ref57" ref-type="bibr">57–61</xref>] by testing from the lowest (default 0.2) to the highest (default 0.8) percentile with a defined step (default 0.1). In joint analysis with combinations of two continuous predictors, we determine optimal cutoffs using a median-anchored greedy (default) or an exhaustive search (described below, and in <xref rid="f2" ref-type="fig">Figure 1</xref>). Because multiple tests are conducted in searching for optimal cutoffs, we apply a <italic toggle="yes">P</italic>-value correction method to control for false positive probability (described below).</p>
        <list list-type="simple">
          <list-item>
            <p>(i) Median-anchored greedy search: we construct a 2D grid using percentiles of both predictors (<xref rid="f2" ref-type="fig">Figure 1</xref>). Next, we determine the starting point for a greedy search by locating the minimum <italic toggle="yes">P</italic>-value computed from testing each percentile in predictor B against the median percentile in predictor A. Then, we test the nearest three unexplored points; if a lower <italic toggle="yes">P</italic>-value is found, we move the search to that newly found minimum <italic toggle="yes">P</italic>-value point and test the nearest unexplored points until no lower <italic toggle="yes">P</italic>-value can be found. We test only percentile combinations that have at least 10% (default) of total cases in each subgroup or subgroup combination.</p>
          </list-item>
          <list-item>
            <p>(ii) Exhaustive search: We construct a 2D grid using percentiles of both predictors (<xref rid="f2" ref-type="fig">Figure 1</xref>). Next, we determine the optimal percentile combination by locating the minimum <italic toggle="yes">P</italic>-value computed from testing each percentile in predictor B against each percentile in predictor A. As for the greedy search above, we only test percentile combinations giving at least 10% (default) of total cases in each subgroup or subgroup combination.</p>
          </list-item>
        </list>
        <p>We also offer customizable analysis with user-selected percentile cutoffs. However, we recommend using the default minimum <italic toggle="yes">P</italic>-value search because: (i) studies have shown its advantages over an arbitrarily prespecified cutoff [<xref rid="ref57" ref-type="bibr">57–61</xref>], and (ii) if a percentile (e.g. median) or percentile combination (e.g. median-median) was optimal to stratify the patient samples, the search would detect it and use it.</p>
        <p>In joint analysis with two continuous genomic predictors, we recommend ‘median-anchored greedy search’ over ‘exhaustive search’. Exhaustive search can find the best cutoff values if there is enough statistical power (i.e. a large enough sample size). However, this approach involves many tests, which can lead to a heavy penalty in adjusting for multiple testing, i.e. can result in insufficient statistical power. In practice, most comparisons only have limited sample sizes; hence, we propose a balanced choice, the ‘median-anchored greedy search’. This smart search strategy involves many fewer tests to address the issue of losing statistical power due to multiple testing, while minimally sacrificing the opportunity to investigate good candidate cutoff values.</p>
      </sec>
      <sec id="sec14">
        <title>Permutation-based multiple testing adjustment for optimally selected cutoffs</title>
        <p>We use permutations to correct the multiple testing that arises from assessing a sequence of candidate cutoffs with the minimum <italic toggle="yes">P</italic>-value method [<xref rid="ref62" ref-type="bibr">62</xref>]. Briefly, we randomly permute outcomes values (in TCGA and TARGET, survival days and censoring status; in DepMap, gene perturbation effects or drug sensitivity scores) over the samples, and determine the new optimal cutoff. We repeat this a defined number of times (default: <italic toggle="yes">n</italic> = 100) to generate a null distribution of minimum <italic toggle="yes">P</italic>-values, i.e. the empirical distribution for the minimum <italic toggle="yes">P</italic>-values when there is no association between the biomarkers and the survival outcomes. Then, we calculate an empirically adjusted <italic toggle="yes">P</italic>-value (<italic toggle="yes">P</italic>.adj) by comparing the observed minimum <italic toggle="yes">P</italic>-value to this empirical null distribution. To speed up the calculation, we use mclapply v4.0.3 [<xref rid="ref63" ref-type="bibr">63</xref>] for parallel processing.</p>
      </sec>
    </sec>
    <sec id="sec15">
      <title>Differential dependency and cell viability analysis</title>
      <p>For two-group comparisons, we used a two-tailed two-sample Wilcoxon test (wilcox.test [<xref rid="ref63" ref-type="bibr">63</xref>]) to assess the differences in dependency scores (CRISPR-Cas9, RNAi) or cell viabilities (drug sensitivity assays). Comparisons between more than two groups are assessed with a Kruskal–Wallis rank sum test (kruskal.test [<xref rid="ref63" ref-type="bibr">63</xref>]) to test the overall significance of any difference between subgroups. Because dependency scores and cell viability data are skewed to the left (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 2A–C</xref>, see Supplementary Data available online at <italic toggle="yes">Briefings in Bioinformatics</italic> online), we use nonparametric Wilcoxon and Kruskal–Wallis rank sum tests, which require no distribution assumption. For continuous genomic predictors, we determine optimal cutoffs and apply a multiple testing adjustment, as described above.</p>
    </sec>
    <sec id="sec16">
      <title>Customizable and interactive visualizations</title>
      <p>We generate survival curves and forest plots with survminer v0.4.9 [<xref rid="ref64" ref-type="bibr">64</xref>]. We also create interactive visualizations for further analysis with ggplot2 v3.3.5 [<xref rid="ref65" ref-type="bibr">65</xref>] and plotly v4.9.4.1 (<ext-link xlink:href="https://plotly.com/" ext-link-type="uri">https://plotly.com/</ext-link>) (<xref rid="f2" ref-type="fig">Figure 1</xref>): (i) density and box plots showing the distribution of dependency scores (DepMap); (ii) line plots showing <italic toggle="yes">P</italic>-values and HRs tracked over percentiles; (iii) heatmaps showing <italic toggle="yes">P</italic>-values and HRs searched over percentile combinations; (iv) bar plots showing the distribution of somatic mutations; (v) scatter plots analyzing correlations between two continuous predictors and (vi) violin plots assessing differences in values of a continuous predictor between two categories (e.g. expression differences of a pathway between mutated <italic toggle="yes">versus</italic> nonmutated groups). Each visualization is customizable with its own plotting parameters (e.g. colors, time intervals on the <italic toggle="yes">x</italic>-axis), and data points of interest are searchable and highlightable in box, scatter and violin plots.</p>
      <sec id="sec17">
        <title>Correlation analysis in scatter plots</title>
        <p>We apply Pearson’s product–moment correlation (default), Kendall’s rank correlation tau and Spearman’s rank correlation rho (cor.test [<xref rid="ref63" ref-type="bibr">63</xref>]) to measure correlations between two continuous predictors.</p>
      </sec>
      <sec id="sec18">
        <title>Group mean analysis in violin plots</title>
        <p>We apply a two-tailed two-sample Wilcoxon test (wilcox.test [<xref rid="ref63" ref-type="bibr">63</xref>]) to assess the differences in a continuous predictor (e.g. gene expression) between two subcategories of a categorical predictor (e.g. loss-of-function mutations versus other). As above, we chose a nonparametric Wilcoxon test because it requires no distribution assumption (examples of nonnormalities are provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 2D and E</xref>, see Supplementary Data available online at <italic toggle="yes">Briefings in Bioinformatics</italic> online).</p>
      </sec>
    </sec>
    <sec id="sec19">
      <title>Web interface implementation</title>
      <p>We implement the web interface of cSurvival using Apache (v2.4.29, <ext-link xlink:href="https://httpd.apache.org" ext-link-type="uri">https://httpd.apache.org</ext-link>), R (v4.0.3, <ext-link xlink:href="https://www.r-project.org/" ext-link-type="uri">https://www.r-project.org/</ext-link>), R Shiny (v1.5.0, <ext-link xlink:href="https://CRAN.R-project.org/package=shiny" ext-link-type="uri">https://CRAN.R-project.org/package=shiny</ext-link>) and R Shiny Server (v1.5.14.948, <ext-link xlink:href="https://rstudio.com/products/shiny/download-server/" ext-link-type="uri">https://rstudio.com/products/shiny/download-server/</ext-link>). We use plumber (v1.1.0, <ext-link xlink:href="https://CRAN.R-project.org/package=plumber" ext-link-type="uri">https://CRAN.R-project.org/package=plumber</ext-link>) and pm2 (v5.1.1, <ext-link xlink:href="https://pm2.keymetrics.io/" ext-link-type="uri">https://pm2.keymetrics.io/</ext-link>) to host cSurvival’s API.</p>
    </sec>
  </sec>
  <sec id="sec20">
    <title>Results</title>
    <p>In cSurvival v1.0.0, we have aggregated the following data. From the TCGA and the TARGET projects, clinical and multiomics data of 10 973 adult and 4995 pediatric tumors across 40 cancer types (33 adult, 7 pediatric). From the DepMap project [<xref rid="ref38" ref-type="bibr">38</xref>]: (i) multiomics data of 1747 cell lines; (ii) cell viability data from 4686 drug compounds screened in 578 cell lines; and (iii) genetic perturbation data from 17 393 and 17 309 genes screened via CRISPR-Cas9 and RNAi in 1032 and 712 cell lines, respectively. From the eVITTA project v1.2.13 [<xref rid="ref42" ref-type="bibr">42</xref>]: 120 953 GSs (<xref rid="f5" ref-type="fig">Figure 2</xref>).</p>
    <fig position="float" id="f5">
      <label>Figure 2</label>
      <caption>
        <p>Overview of the cSurvival database. (<bold>A</bold>) The circos plot (rendered with circularize [<xref rid="ref82" ref-type="bibr">82</xref>]) shows the distribution of tumor and cell line datasets: Inner to outer: example outputs; project names; histograms showing the total number of cases per study; box plots showing the distribution of survival days (TCGA, TARGET) or dependency scores/cell viabilities (DepMap), numbers denoting 3-, 5- and 10-year survival rates from inner to outer; study names. (<bold>B</bold>) The histogram shows the distribution of GS libraries from eVITTA; numbers denote the number of GSs per library. DepMap, Dependency Map; eVITTA, easy Visualization and Inference Toolbox for Transcriptome Analysis.</p>
      </caption>
      <graphic xlink:href="bbac090f2" position="float"/>
    </fig>
    <p>Here, we report three case studies to demonstrate cSurvival’s unique abilities in:</p>
    <list list-type="simple">
      <list-item>
        <p>(i) GS-level predictor analysis;</p>
      </list-item>
      <list-item>
        <p>(ii) joint analysis with two genomic predictors;</p>
      </list-item>
      <list-item>
        <p>(iii) integration of clinical and laboratory data to generate biological insights.</p>
      </list-item>
    </list>
    <p>First, we tested cSurvival’s analytical pipeline at the level of GSs. We recapitulated the finding that high expression of an autophagy signature [Gene Ontology (GO): 0010506] is associated with poor OS in colorectal cancers [colon adenocarcinoma (TCGA-COAD) and rectum adenocarcinoma (TCGA-READ)] (<xref rid="f6" ref-type="fig">Figure 3A and B</xref>; percentile tracking in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 3A</xref>, see Supplementary Data available online at <italic toggle="yes">Briefings in Bioinformatics</italic> online) [<xref rid="ref36" ref-type="bibr">36</xref>].</p>
    <fig position="float" id="f6">
      <label>Figure 3</label>
      <caption>
        <p>Case studies on autophagy-dependent survival in colorectal cancer and synergistic effects between high expression of <italic toggle="yes">SLC7A11</italic> and <italic toggle="yes">SLC2A1</italic> in liver cancer. The survival curves (<bold>A</bold>) and forest plots (<bold>B</bold>), censored at 10 years, show correlation between GO autophagy signature (GO: 0010506) and OS in colorectal cancers (TCGA-COAD and READ) (<italic toggle="yes">P</italic> = 0.012, <italic toggle="yes">P</italic>.adj = 0.03, KM log-rank; HR = 1.7, <italic toggle="yes">P</italic> = 0.017, <italic toggle="yes">P</italic>.adj = 0.05, Cox PH likelihood ratio). The scatter plot (<bold>C</bold>) shows a moderate correlation between expression of <italic toggle="yes">SLC7A11</italic> and <italic toggle="yes">SLC2A1</italic> (Pearson’s correlation coefficient = 0.35, <italic toggle="yes">P</italic> = 3.2e−12). The survival curves (<bold>D</bold>), censored at 10 years, show significant differences in OS rates among patients with liver hepatocellular carcinoma (TCGA-LIHC) stratified by <italic toggle="yes">SLC7A11</italic> and <italic toggle="yes">SLC2A1</italic> expression levels (<italic toggle="yes">P</italic> = 1e−07, <italic toggle="yes">P</italic>.adj &lt; 0.01, KM log-rank; <italic toggle="yes">P</italic> = 1.7e−06, <italic toggle="yes">P</italic>.adj &lt; 0.01, Cox PH likelihood ratio). The survival curves (<bold>E</bold>) and forest plots (<bold>F</bold>), censored at 10 years, show a lower OS rate in TCGA-LIHC patients with high expression of both <italic toggle="yes">SLC7A11</italic> and <italic toggle="yes">SLC2A1</italic> than in patients with low expression of <italic toggle="yes">SLC7A11</italic> and/or <italic toggle="yes">SLC2A1</italic> (<italic toggle="yes">P</italic> = 4.2e−08, <italic toggle="yes">P</italic>.adj &lt; 0.01, KM log-rank; HR = 3.38, <italic toggle="yes">P</italic> = 4.9e−06, <italic toggle="yes">P</italic>.adj &lt; 0.01, Cox PH likelihood ratio). GO, gene ontology; COAD, colon adenocarcinoma; READ, rectum adenocarcinoma; <italic toggle="yes">P</italic>, <italic toggle="yes">P</italic>-value; <italic toggle="yes">P</italic>.adj, adjusted <italic toggle="yes">P</italic>-value; KM, Kaplan–Meier; PH, proportional-hazard; HR, hazard ratio; LIHC, liver hepatocellular carcinoma.</p>
      </caption>
      <graphic xlink:href="bbac090f3" position="float"/>
    </fig>
    <p>Second, we performed joint analysis with gene expression data of solute carrier family 7 member 11 (<italic toggle="yes">SLC7A11</italic>) and solute carrier family 2 member 1 (<italic toggle="yes">SLC2A1</italic>, also known as <italic toggle="yes">glucose transporter 1 (GLUT1)</italic>) in liver hepatocellular carcinoma (TCGA-LIHC). We found that <italic toggle="yes">SLC7A11</italic> and <italic toggle="yes">SLC2A1</italic> showed a moderate correlation in their expressions (<xref rid="f6" ref-type="fig">Figure 3C</xref>), and that patients with higher expression of both <italic toggle="yes">SLC7A11</italic> and <italic toggle="yes">SLC2A1</italic> showed significantly lower survival rates than patients with low expression of <italic toggle="yes">SLC7A11</italic> and/or <italic toggle="yes">SLC2A1</italic> (<xref rid="f6" ref-type="fig">Figure 3D–F</xref>; percentile tracking in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 3B and C</xref>, see Supplementary Data available online at <italic toggle="yes">Briefings in Bioinformatics</italic> online). The synergistic negative effects between high expressions of <italic toggle="yes">SLC7A11</italic> and <italic toggle="yes">SLC2A1</italic> on outcomes were also observed in several other cancer types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 4</xref>, see Supplementary Data available online at <italic toggle="yes">Briefings in Bioinformatics</italic> online). These results are consistent with the finding that cotargeting the <sc>l</sc>-cystine importer <italic toggle="yes">SLC7A11</italic> and the glucose transporter <italic toggle="yes">SLC2A1</italic> induces synthetic lethal cell death in glucose-deprived cell lines [<xref rid="ref66" ref-type="bibr">66</xref>].</p>
    <p>Third, to illustrate cSurvival’s integrated workflow, and to show how cSurvival can bridge clinical and cell line studies, we assessed the Nrf2 [nuclear factor erythroid 2 related factor 2 (<italic toggle="yes">NFE2L2</italic>)]-Keap1 [Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1 (<italic toggle="yes">KEAP1</italic>)] signaling pathway. Nrf2 is a master orchestrator of oxidative homeostasis and is primarily regulated by Keap1 [<xref rid="ref67" ref-type="bibr">67</xref>]. In cancers, <italic toggle="yes">KEAP1</italic> is frequently mutated, resulting in constitutively active Nrf2 that protects cancer cells from chemotherapeutic agents and facilitates cancer progression [<xref rid="ref67" ref-type="bibr">67</xref>]. For example, Nrf2 is aberrantly activated in ~30% of human lung cancers [<xref rid="ref68" ref-type="bibr">68</xref>]. Using cSurvival, we found that expression or mutation of <italic toggle="yes">NFE2L2</italic> and <italic toggle="yes">KEAP1</italic> themselves showed no association with patient OS (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 5</xref>, see Supplementary Data available online at <italic toggle="yes">Briefings in Bioinformatics</italic> online). However, high expression of genes in the Nrf2-antioxidant response element (ARE) pathway (WikiPathways: WP4357) correlated strongly with poor prognosis in lung adenocarcinoma patients (<xref rid="f10" ref-type="fig">Figure 4A and B</xref>). Consistent with this clinical finding, in DepMap’s experimental genetic perturbation screens, <italic toggle="yes">KEAP1</italic>-mutated lung cancer cell lines were more sensitive to <italic toggle="yes">NFE2L2</italic> knockout and knockdown (<xref rid="f10" ref-type="fig">Figure 4C–F</xref>), consistent with <italic toggle="yes">KEAP1</italic> mutation being the main driver for oncogenic Nrf2 activation [<xref rid="ref69" ref-type="bibr">69</xref>, <xref rid="ref70" ref-type="bibr">70</xref>]. Likewise, cell lines with higher expression of Nrf2–ARE pathway genes showed greater resistance to a potent oxidative stress inducer, menadione (BRD-K78126613-001-28-5) (<xref rid="f11" ref-type="fig">Figure 5A and B</xref>) [<xref rid="ref71" ref-type="bibr">71</xref>]. Moreover, cSurvival analysis showed that the male A549 and the female H2172 cell lines both harbor deactivating <italic toggle="yes">KEAP1</italic> mutations, manifest high Nrf2–ARE pathway expression, and show relatively high resistance to menadione (<xref rid="f11" ref-type="fig">Figure 5</xref>). These findings are consistent with published reports that the A549 cell line is an excellent tool for studies on Nrf2 regulation and activity [<xref rid="ref72" ref-type="bibr">72–74</xref>]; extending this, cSurvival analysis suggests that the female H2172 cell line is another excellent model to study Nrf2 function, and can be used in conjunction with A549 to study sex-specific effects (<xref rid="f11" ref-type="fig">Figure 5</xref>).</p>
    <fig position="float" id="f10">
      <label>Figure 4</label>
      <caption>
        <p>High expression of the Nrf2–ARE pathway correlates with poor prognosis and <italic toggle="yes">KEAP1</italic> mutation in lung cancers. The survival curves (<bold>A</bold>) and forest plot (<bold>B</bold>), censored at 10 years, show correlation between high expression of the Nrf2–ARE pathway (WikiPathways: WP4357) and poor prognosis in TCGA-LUAD cases (<italic toggle="yes">P</italic> = 0.00015, <italic toggle="yes">P</italic>.adj &lt; 0.01, KM log-rank; HR = 1.84, <italic toggle="yes">P</italic> = 0.00027, <italic toggle="yes">P</italic>.adj &lt; 0.01, Cox PH likelihood ratio). Shades reflect 95% confidence intervals in survival curves in (<bold>A</bold>). The density and box plots show lung cancer cell lines with an inactivating <italic toggle="yes">KEAP1</italic> mutation (red) being more sensitive to <italic toggle="yes">NFE2L2</italic> CRISPR-Cas9 knockout (<italic toggle="yes">P</italic> = 4.1e−07, two-tailed Wilcoxon test) (<bold>C</bold>, <bold>D</bold>) and RNAi knockdown (<italic toggle="yes">P</italic> = 8.4e−05, two-tailed Wilcoxon test) (<bold>E, F</bold>). ARE, antioxidant response element; LUAD, lung adenocarcinoma; <italic toggle="yes">P</italic>, <italic toggle="yes">P</italic>-value; <italic toggle="yes">P</italic>.adj, adjusted <italic toggle="yes">P</italic>-value; KM, Kaplan–Meier; HR, hazard ratio; PH, proportional-hazard; RNAi, RNA interference; Chronos, an algorithm for inferring gene knockout fitness effects; DEMETER2, gene dependency estimates for RNAi datasets.</p>
      </caption>
      <graphic xlink:href="bbac090f4" position="float"/>
    </fig>
    <fig position="float" id="f11">
      <label>Figure 5</label>
      <caption>
        <p>The male A549 and the female H2172 cell lines are top candidates for studies on Nrf2 regulation and activity. The density (<bold>A</bold>) and box (<bold>B</bold>) plots show that lung cancer cell lines with higher expression levels of Nrf2–ARE pathway genes exhibit higher resistance to the oxidative stress inducer menadione (BRD-K78126613-001-28-5, <italic toggle="yes">P</italic> = 0.00014, <italic toggle="yes">P</italic>.adj &lt; 0.01, two-tailed Wilcoxon test). The density (<bold>C</bold>) and box (<bold>D</bold>) plots show that lung cancer cell lines with different <italic toggle="yes">KEAP1</italic> mutation status and expression levels of Nrf2–ARE pathway genes show sensitivity differences to <italic toggle="yes">NFE2L2</italic> knockout (<italic toggle="yes">P</italic> = 2.6e−06, <italic toggle="yes">P</italic>.adj &lt; 0.01, Kruskal–Wallis rank sum test). The A549 and the H2172 cell lines are highlighted in a triangle shape with a darker color and labeled in the box plots. ARE, antioxidant response element; <italic toggle="yes">P</italic>, <italic toggle="yes">P</italic>-value; <italic toggle="yes">P</italic>.adj, adjusted <italic toggle="yes">P</italic>-value; Chronos, an algorithm for inferring gene knockout fitness effects.</p>
      </caption>
      <graphic xlink:href="bbac090f5" position="float"/>
    </fig>
    <p>Together, these analyses demonstrate cSurvival’s unique ability to support biomarker prognosis and interaction analysis via gene- and GS-level approaches, and to facilitate integrating clinical and experimental biomedical studies. See the cSurvival user guide (<ext-link xlink:href="https://tau.cmmt.ubc.ca/cSurvival/help.html" ext-link-type="uri">https://tau.cmmt.ubc.ca/cSurvival/help.html</ext-link>) for:</p>
    <p>(i) detailed steps for the reported case studies;</p>
    <p>(ii) application cases for single biomarker analysis with each type of molecular data;</p>
    <p>(iii) application cases for biomarker interaction analysis with two different types of molecular data, including DNA methylation and miRNA expression, mutation and miRNA expression, mutation and CN variation, and GS expression and gene expression.</p>
  </sec>
  <sec id="sec21">
    <title>Discussion</title>
    <p>Cancer arises from accumulated genetic and epigenetic alterations, creating interactions that endow cancer cells with growth and survival advantages. Such functional relationships happen not only between genes, but also between GSs, or between genes and GSs. Correspondingly, regimens that combine multiple drugs that target different genes/GSs have emerged as more effective and less toxic than monotherapy approaches [<xref rid="ref30" ref-type="bibr">30</xref>, <xref rid="ref31" ref-type="bibr">31</xref>]. Pinpointing genetic interactions in cancers is thus an important research goal.</p>
    <p>Here, we developed cSurvival, an open-source framework to identify potential genetic interactions and survey preclinical cell line tools. cSurvival offers innovative algorithms that can assess interactions between many types of cancer biomarkers, including GSs, as well as a curated database that combines clinical and experimental data to generate synergistic biological insights. As shown by the three case studies, cSurvival sheds light on genetic interactions in cancers and facilitates the identification of preclinical cell line tools for mechanistic studies.</p>
    <p>For long-term sustainability, we have automated data extraction from the NCI GDC (<ext-link xlink:href="https://gdc.cancer.gov" ext-link-type="uri">https://gdc.cancer.gov</ext-link>) [<xref rid="ref48" ref-type="bibr">48</xref>] and will continuously follow consortium efforts/GDC evolution, so that cSurvival uses up-to-date processing pipelines, human reference genomes and gene annotations.</p>
    <p>Despite the advances described herein, cSurvival has certain limitations. For example, the current version is designed for one query (a gene or a gene combination) at a time. For continuous genomic predictors, we have corrected the inflated false positive rate due to exploring multiple cutoff values for each gene/gene combination. However, when testing many genes/gene combinations, users should apply another layer of multiple testing adjustment. This is similar to a <italic toggle="yes">t</italic>-test, which is designed to compare two groups; when using a <italic toggle="yes">t</italic>-test to test many pairs of groups, a multiple testing adjustment needs to be applied outside of these <italic toggle="yes">t</italic>-tests. For example, when using cSurvival to test ten genes/gene combinations, and each test returns a <italic toggle="yes">P</italic>-value (or adjusted <italic toggle="yes">P</italic>-value for continuous genomic predictors), one can do the outer multiple testing adjustment using the <italic toggle="yes">P</italic>. adjust function in R [<xref rid="ref63" ref-type="bibr">63</xref>]. Note that a Bonferroni correction may be more appropriate for a smaller number of genes/gene combinations, while a false discovery rate (FDR) correction may be more appropriate for a larger number. The <italic toggle="yes">P</italic>. adjust function offers a range of correction methods, including Bonferroni and FDR. Future versions of cSurvival may extend to batch analysis with corrections for multiple testing. In addition, cohorts from TCGA and TARGET were largely from North America. To address ethnicity [<xref rid="ref75" ref-type="bibr">75</xref>] heterogeneities in human populations, we plan to expand the cSurvival database, incorporating resources such as the International Cancer Genome Consortium [<xref rid="ref76" ref-type="bibr">76</xref>] and cohorts from the Gene Expression Omnibus (<ext-link xlink:href="https://www.ncbi.nlm.nih.gov/geo/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/geo/</ext-link>). Future versions of cSurvival may also address the challenges of immunogenomics [<xref rid="ref77" ref-type="bibr">77</xref>] and may integrate cellular signatures from the Connectivity Map [<xref rid="ref78" ref-type="bibr">78</xref>, <xref rid="ref79" ref-type="bibr">79</xref>].</p>
    <p>Although we built cSurvival as a web resource to analyze molecular biomarkers in published cancer datasets, its source code could be adapted to analyze unpublished or protected data locally. Its algorithms for searching for optimal cutoffs for interaction analysis could also be applied to other types of (bio)markers and/or other diseases, e.g. to data from biomedical imaging [<xref rid="ref80" ref-type="bibr">80</xref>] or drug cocktail effect assessment [<xref rid="ref81" ref-type="bibr">81</xref>], which sometimes involve combinations of continuous and/or categorical variables.</p>
    <p>In summary, cSurvival offers a curated database and innovative analytical pipelines to examine cancer biomarkers at high resolution. It complements existing resources such as cBioPortal [<xref rid="ref9" ref-type="bibr">9</xref>] and enhances mechanistic investigation of malignancy etiologies using clinical correlations. Its intuitive yet flexible web interface makes it a valuable tool for experimental and clinical researchers alike.</p>
    <boxed-text id="box01" position="float">
      <sec id="sec24z">
        <title>Key Points</title>
        <list list-type="bullet">
          <list-item>
            <p>We developed cSurvival, an advanced framework using clinical correlations to study biomarker interactions in cancers, with source code and curated datasets freely available for download.</p>
          </list-item>
          <list-item>
            <p>cSurvival includes new algorithms to identify optimal cutoffs for two continuous predictors to stratify patients into risk groups, enabling, for the first time, joint analysis with two genomic predictors.</p>
          </list-item>
          <list-item>
            <p>cSurvival allows survival analysis at the gene set (GS) level with comprehensive and up-to-date GS libraries.</p>
          </list-item>
          <list-item>
            <p>The cSurvival pipeline integrates clinical outcomes data and experimental cancer cell line data to generate synergistic biological insights and to mine for appropriate preclinical cell line tools.</p>
          </list-item>
          <list-item>
            <p>cSurvival is built on a manually curated cancer outcomes database.</p>
          </list-item>
        </list>
      </sec>
    </boxed-text>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>Supplementary_Figures_bbac090</label>
      <media xlink:href="supplementary_figures_bbac090.doc">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="sup2" position="float" content-type="local-data">
      <label>TableS1_bbac090</label>
      <media xlink:href="tables1_bbac090.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="bbac090-ack">
    <title>Acknowledgement</title>
    <p>We thank P.W. Laird (Van Andel Institute, Grand Rapids, MI), T. Lichtenberg (University of Chicago, Chicago, IL), C.A. Maxwell (The University of British Columbia, Vancouver, BC), H. Shen (Van Andel Institute, Grand Rapids, MI), Z. Zhou (The Chinese University of Hong Kong, Shatin, HK) and Taubert lab members for critical comments on the manuscript. <xref rid="f2" ref-type="fig">Figure 1</xref> was created with <ext-link xlink:href="http://BioRender.com" ext-link-type="uri">BioRender.com</ext-link>, Toronto, Canada.</p>
  </ack>
  <sec id="sec26">
    <title>Funding</title>
    <p>Canadian Institutes of Health Research (CIHR; PJT-153199); Natural Sciences and Engineering Research Council of Canada (NSERC; RGPIN-2018-05133 to S.T., RGPIN-2017-04722 to X.Z.); Canada Research Chair (No. 950231363 to X.Z.); British Columbia Children’s Hospital Research Institute Investigator Grant Award Program award (to S.T.); Canada Research Chairs program (to S.J.M.J.). Funding for open access charges: Canadian Institutes of Health Research (CIHR; PJT-153199).</p>
  </sec>
  <sec sec-type="data-availability" id="sec22">
    <title>Data Availability</title>
    <p>cSurvival (<ext-link xlink:href="https://tau.cmmt.ubc.ca/cSurvival" ext-link-type="uri">https://tau.cmmt.ubc.ca/cSurvival</ext-link>) is free and open to all users and has no login requirement. The source code for building cSurvival’s framework and database is available at GitHub (<ext-link xlink:href="https://github.com/easygsea/cSurvival.git" ext-link-type="uri">https://github.com/easygsea/cSurvival.git</ext-link>).</p>
  </sec>
  <notes id="bio3">
    <title>Author Biographies</title>
    <p><bold>Xuanjin Cheng</bold> is a researcher in the Department of Medical Genetics at The University of British Columbia. Her research combines bioinformatics and molecular biology to study gene regulation in development and disease.</p>
    <sec sec-type="author-bio" id="sec28a">
      <p><bold>Yongxing Liu</bold> is a fourth-year Mathematics student at The University of British Columbia. He is interested in data science, machine learning and bioinformatics.</p>
    </sec>
    <sec sec-type="author-bio" id="sec29a">
      <p><bold>Jiahe Wang</bold> is currently a Computer Science master student at Simon Fraser University with a concentration on big data and machine learning.</p>
    </sec>
    <sec sec-type="author-bio" id="sec30a">
      <p><bold>Yujie Chen</bold> is an undergraduate student majoring in Statistics at The University of British Columbia, and her research interest is machine learning and bioinformatics.</p>
    </sec>
    <sec sec-type="author-bio" id="sec31a">
      <p><bold>Andrew Gordon Robertson</bold> was an analyst with BC Cancer’s Canada’s Michael Smith Genome Sciences Centre in Vancouver, Canada. He has contributed to many The Cancer Genome Atlas, PanCancer Atlas and GDAN projects and publications. He is currently an analyst with Dxige Research Inc., in Courtenay, BC, Canada.</p>
    </sec>
    <sec sec-type="author-bio" id="sec32a">
      <p><bold>Xuekui Zhang</bold> is a Tier 2 Canada Research Chair in biostatistics and bioinformatics and an assistant professor in the Department of Mathematics and Statistics at the University of Victoria.</p>
    </sec>
    <sec sec-type="author-bio" id="sec33a">
      <p><bold>Steven J.M. Jones</bold> is a codirector and the head of bioinformatics at the Genome Sciences Centre, BC Cancer. He is also a professor in the Department of Medical Genetics at The University of British Columbia.</p>
    </sec>
    <sec sec-type="author-bio" id="sec34a">
      <p><bold>Stefan Taubert</bold> is an associate professor in the Department of Medical Genetics at The University of British Columbia who studies gene regulation in health and disease.</p>
    </sec>
  </notes>
  <ref-list id="bib1">
    <title>References</title>
    <ref id="ref1">
      <label>1.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Kleinbaum</surname><given-names>DG</given-names></string-name>, <string-name><surname>Klein</surname><given-names>M</given-names></string-name></person-group>. <source>Survival Analysis: A Self-Learning Text</source>, <edition>3rd</edition> edn, Springer, New York <year>2012</year>.</mixed-citation>
    </ref>
    <ref id="ref2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schober</surname><given-names>P</given-names></string-name>, <string-name><surname>Vetter</surname><given-names>TR</given-names></string-name></person-group>. <article-title>Survival analysis and interpretation of time-to-event data: the tortoise and the hare</article-title>. <source>Anesth Analg</source><year>2018</year>;<volume>127</volume>:<fpage>792</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">30015653</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Györffy</surname><given-names>B</given-names></string-name>, <string-name><surname>Lanczky</surname><given-names>A</given-names></string-name>, <string-name><surname>Eklund</surname><given-names>AC</given-names></string-name>, <etal>et al.</etal></person-group><article-title>An online survival analysis tool to rapidly assess the effect of 22 277 genes on breast cancer prognosis using microarray data of 1809 patients</article-title>. <source>Breast Cancer Res Treat</source><year>2010</year>;<volume>123</volume>:<fpage>725</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">20020197</pub-id></mixed-citation>
    </ref>
    <ref id="ref4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>G</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Comprehensive review of web servers and bioinformatics tools for cancer prognosis analysis</article-title>. <source>Front Oncol</source><year>2020</year>;<volume>10</volume>:<fpage>68</fpage>.<pub-id pub-id-type="pmid">32117725</pub-id></mixed-citation>
    </ref>
    <ref id="ref5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tomczak</surname><given-names>K</given-names></string-name>, <string-name><surname>Czerwińska</surname><given-names>P</given-names></string-name>, <string-name><surname>Wiznerowicz</surname><given-names>M</given-names></string-name></person-group>. <article-title>The cancer Genome atlas (TCGA): an immeasurable source of knowledge</article-title>. <source>Contemp Oncol</source><year>2015</year>;<volume>19</volume>:<fpage>A68</fpage>–<lpage>77</lpage>.</mixed-citation>
    </ref>
    <ref id="ref6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name><surname>Lichtenberg</surname><given-names>T</given-names></string-name>, <string-name><surname>Hoadley</surname><given-names>KA</given-names></string-name>, <etal>et al.</etal></person-group><article-title>An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics</article-title>. <source>Cell</source><year>2018</year>;<volume>173</volume>:<fpage>400</fpage>, <elocation-id>e11</elocation-id>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">29625055</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Genome</surname><given-names>OC</given-names></string-name></person-group>. <article-title>Therapeutically applicable research to generate effective treatments</article-title>. <source>Off Cancer Genomics</source><year>2013</year>.</mixed-citation>
    </ref>
    <ref id="ref8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cerami1</surname><given-names>E</given-names></string-name>, <string-name><surname>Gao</surname><given-names>J</given-names></string-name>, <string-name><surname>Dogrusoz</surname><given-names>U</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title>. <source>Cancer Discov</source><year>2012</year>;<volume>2</volume>:<fpage>401</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">22588877</pub-id></mixed-citation>
    </ref>
    <ref id="ref9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gao</surname><given-names>J</given-names></string-name>, <string-name><surname>Aksoy</surname><given-names>BA</given-names></string-name>, <string-name><surname>Dogrusoz</surname><given-names>U</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title>. <source>Sci Signal</source><year>2013</year>;<volume>6</volume>:<fpage>pl1</fpage>.<pub-id pub-id-type="pmid">23550210</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>G</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Yang</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>OSpaad: an online tool to perform survival analysis by integrating gene expression profiling and long-term follow-up data of 1319 pancreatic carcinoma patients</article-title>. <source>Mol Carcinog</source><year>2020</year>;<volume>59</volume>:<fpage>304</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">31912599</pub-id></mixed-citation>
    </ref>
    <ref id="ref11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname><given-names>S-J</given-names></string-name>, <string-name><surname>Yoon</surname><given-names>B-H</given-names></string-name>, <string-name><surname>Kim</surname><given-names>S-K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>GENT2: an updated gene expression database for normal and tumor tissues</article-title>. <source>BMC Med Genomics</source><year>2019</year>;<volume>12</volume>:<fpage>101</fpage>.<pub-id pub-id-type="pmid">31296229</pub-id></mixed-citation>
    </ref>
    <ref id="ref12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goswami</surname><given-names>CP</given-names></string-name>, <string-name><surname>Nakshatri</surname><given-names>H</given-names></string-name></person-group>. <article-title>PROGgeneV2: enhancements on the existing database</article-title>. <source>BMC Cancer</source><year>2014</year>;<volume>14</volume>:<fpage>970</fpage>.<pub-id pub-id-type="pmid">25518851</pub-id></mixed-citation>
    </ref>
    <ref id="ref13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aguirre-Gamboa</surname><given-names>R</given-names></string-name>, <string-name><surname>Gomez-Rueda</surname><given-names>H</given-names></string-name>, <string-name><surname>Martínez-Ledesma</surname><given-names>E</given-names></string-name>, <etal>et al.</etal></person-group><article-title>SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis</article-title>. <source>PLoS One</source><year>2013</year>;<volume>8</volume>:<fpage>e74250</fpage>.<pub-id pub-id-type="pmid">24066126</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mizuno</surname><given-names>H</given-names></string-name>, <string-name><surname>Kitada</surname><given-names>K</given-names></string-name>, <string-name><surname>Nakai</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>PrognoScan: a new database for meta-analysis of the prognostic value of genes</article-title>. <source>BMC Med Genom</source><year>2009</year>;<volume>2</volume>:<fpage>18</fpage>.</mixed-citation>
    </ref>
    <ref id="ref15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nagy</surname><given-names>Á</given-names></string-name>, <string-name><surname>Munkácsy</surname><given-names>G</given-names></string-name>, <string-name><surname>Győrffy</surname><given-names>B</given-names></string-name></person-group>. <article-title>Pancancer survival analysis of cancer hallmark genes</article-title>. <source>Sci Rep</source><year>2021</year>;<volume>11</volume>:<fpage>6047</fpage>.<pub-id pub-id-type="pmid">33723286</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>C-J</given-names></string-name>, <string-name><surname>Hu</surname><given-names>F-F</given-names></string-name>, <string-name><surname>Xia</surname><given-names>M-X</given-names></string-name>, <etal>et al.</etal></person-group><article-title>GSCALite: a web server for gene set cancer analysis</article-title>. <source>Bioinformatics</source><year>2018</year>;<volume>34</volume>:<fpage>3771</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="pmid">29790900</pub-id></mixed-citation>
    </ref>
    <ref id="ref17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chandrashekar</surname><given-names>DS</given-names></string-name>, <string-name><surname>Bashel</surname><given-names>B</given-names></string-name>, <string-name><surname>Balasubramanya</surname><given-names>SAH</given-names></string-name>, <etal>et al.</etal></person-group><article-title>UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses</article-title>. <source>Neoplasia N Y N</source><year>2017</year>;<volume>19</volume>:<fpage>649</fpage>–<lpage>58</lpage>.</mixed-citation>
    </ref>
    <ref id="ref18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Kang</surname><given-names>B</given-names></string-name>, <string-name><surname>Li</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis</article-title>. <source>Nucleic Acid Res</source><year>2019</year>;<volume>47</volume>:<fpage>W556</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">31114875</pub-id></mixed-citation>
    </ref>
    <ref id="ref19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname><given-names>S</given-names></string-name>, <string-name><surname>Kim</surname><given-names>D</given-names></string-name>, <string-name><surname>Kim</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>CAS-viewer: web-based tool for splicing-guided integrative analysis of multi-omics cancer data</article-title>. <source>BMC Med Genom</source><year>2018</year>;<volume>11</volume>:<fpage>25</fpage>.</mixed-citation>
    </ref>
    <ref id="ref20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anaya</surname><given-names>J</given-names></string-name></person-group>. <article-title>OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs</article-title>. <source>PeerJ Comput Sci</source><year>2016</year>;<volume>2</volume>:<fpage>e67</fpage>.</mixed-citation>
    </ref>
    <ref id="ref21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Craft</surname><given-names>B</given-names></string-name>, <string-name><surname>Hastie</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Visualizing and interpreting cancer genomics data via the Xena platform</article-title>. <source>Nat Biotechnol</source><year>2020</year>;<volume>38</volume>:<fpage>675</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">32444850</pub-id></mixed-citation>
    </ref>
    <ref id="ref22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Baran</surname><given-names>J</given-names></string-name>, <string-name><surname>Cros</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>International cancer Genome consortium data portal—a one-stop shop for cancer genomics data</article-title>. <source>Database J Biol Databases Curation</source><year>2011</year>;<volume>2011</volume>:<fpage>bar026</fpage>.</mixed-citation>
    </ref>
    <ref id="ref23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gentles</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Newman</surname><given-names>AM</given-names></string-name>, <string-name><surname>Liu</surname><given-names>CL</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The prognostic landscape of genes and infiltrating immune cells across human cancers</article-title>. <source>Nat Med</source><year>2015</year>;<volume>21</volume>:<fpage>938</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">26193342</pub-id></mixed-citation>
    </ref>
    <ref id="ref24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wong</surname><given-names>NW</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>OncomiR: an online resource for exploring pan-cancer microRNA dysregulation</article-title>. <source>Bioinformatics</source><year>2018</year>;<volume>34</volume>:<fpage>713</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">29028907</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aure</surname><given-names>MR</given-names></string-name>, <string-name><surname>Fleischer</surname><given-names>T</given-names></string-name>, <string-name><surname>Bjørklund</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer</article-title>. <source>Genome Med</source><year>2021</year>;<volume>13</volume>:<fpage>72</fpage>.<pub-id pub-id-type="pmid">33926515</pub-id></mixed-citation>
    </ref>
    <ref id="ref26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bradburn</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Clark</surname><given-names>TG</given-names></string-name>, <string-name><surname>Love</surname><given-names>SB</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Survival analysis part III: multivariate data analysis – choosing a model and assessing its adequacy and fit</article-title>. <source>Br J Cancer</source><year>2003</year>;<volume>89</volume>:<fpage>605</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">12915864</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname><given-names>X</given-names></string-name>, <string-name><surname>Huang</surname><given-names>R</given-names></string-name>, <string-name><surname>Wu</surname><given-names>X</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Dualmarker: a flexible toolset for exploratory analysis of combinatorial dual biomarkers for clinical efficacy</article-title>. <source>BMC Bioinformat</source><year>2021</year>;<volume>22</volume>:<fpage>127</fpage>.</mixed-citation>
    </ref>
    <ref id="ref28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Magen</surname><given-names>A</given-names></string-name>, <string-name><surname>Sahu</surname><given-names>AD</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JS</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Beyond synthetic lethality: charting the landscape of pairwise gene expression states associated with survival in cancer</article-title>. <source>Cell Rep</source><year>2019</year>;<volume>28</volume>:<fpage>938</fpage>–<lpage>948.e6</lpage>.<pub-id pub-id-type="pmid">31340155</pub-id></mixed-citation>
    </ref>
    <ref id="ref29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>D</given-names></string-name>, <string-name><surname>Yang</surname><given-names>X</given-names></string-name>, <etal>et al.</etal></person-group><article-title>TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target</article-title>. <source>Nat Commun</source><year>2020</year>;<volume>11</volume>:<fpage>3660</fpage>.<pub-id pub-id-type="pmid">32694521</pub-id></mixed-citation>
    </ref>
    <ref id="ref30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mokhtari</surname><given-names>RB</given-names></string-name>, <string-name><surname>Homayouni</surname><given-names>TS</given-names></string-name>, <string-name><surname>Baluch</surname><given-names>N</given-names></string-name>, <etal>et al.</etal></person-group><source>Combination therapy in combating cancer</source>, <source>Oncotarget</source><year>2017</year>;<volume>8</volume>:<fpage>38022</fpage>–<lpage>43</lpage>.</mixed-citation>
    </ref>
    <ref id="ref31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ledford</surname><given-names>H</given-names></string-name></person-group>. <article-title>Cocktails for cancer with a measure of immunotherapy</article-title>. <source>Nature</source><year>2016</year>;<volume>532</volume>:<fpage>162</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">27075078</pub-id></mixed-citation>
    </ref>
    <ref id="ref32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S</given-names></string-name></person-group>. <article-title>Discovery of cancer common and specific driver gene sets</article-title>. <source>Nucleic Acid Res</source><year>2017</year>;<volume>45</volume>:<fpage>e86</fpage>.<pub-id pub-id-type="pmid">28168295</pub-id></mixed-citation>
    </ref>
    <ref id="ref33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A</given-names></string-name>, <string-name><surname>Tamayo</surname><given-names>P</given-names></string-name>, <string-name><surname>Mootha</surname><given-names>VK</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc Natl Acad Sci USA</source><year>2005</year>;<volume>102</volume>:<fpage>15545</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maleki</surname><given-names>F</given-names></string-name>, <string-name><surname>Ovens</surname><given-names>K</given-names></string-name>, <string-name><surname>Hogan</surname><given-names>DJ</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Gene set analysis: challenges, opportunities, and future research</article-title>. <source>Front Genet</source><year>2020</year>;<volume>11</volume>:<fpage>654</fpage>.<pub-id pub-id-type="pmid">32695141</pub-id></mixed-citation>
    </ref>
    <ref id="ref35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname><given-names>X</given-names></string-name>, <string-name><surname>Amos</surname><given-names>CI</given-names></string-name>, <string-name><surname>Frost</surname><given-names>HR</given-names></string-name></person-group>. <article-title>Comparison of pathway and gene-level models for cancer prognosis prediction</article-title>. <source>BMC Bioinformatics</source><year>2020</year>;<volume>21</volume>:<fpage>76</fpage>.<pub-id pub-id-type="pmid">32111152</pub-id></mixed-citation>
    </ref>
    <ref id="ref36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rehman</surname><given-names>SK</given-names></string-name>, <string-name><surname>Haynes</surname><given-names>J</given-names></string-name>, <string-name><surname>Collignon</surname><given-names>E</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy</article-title>. <source>Cell</source><year>2021</year>;<volume>184</volume>:<fpage>226</fpage>, <elocation-id>e21</elocation-id>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">33417860</pub-id></mixed-citation>
    </ref>
    <ref id="ref37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goeman</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Oosting</surname><given-names>J</given-names></string-name>, <string-name><surname>Cleton-Jansen</surname><given-names>A-M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Testing association of a pathway with survival using gene expression data</article-title>. <source>Bioinformatics</source><year>2005</year>;<volume>21</volume>:<fpage>1950</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">15657105</pub-id></mixed-citation>
    </ref>
    <ref id="ref38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tsherniak</surname><given-names>A</given-names></string-name>, <string-name><surname>Vazquez</surname><given-names>F</given-names></string-name>, <string-name><surname>Montgomery</surname><given-names>PG</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Defining a cancer dependency map</article-title>. <source>Cell</source><year>2017</year>;<volume>170</volume>:<fpage>564</fpage>, <elocation-id>e16</elocation-id>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">28753430</pub-id></mixed-citation>
    </ref>
    <ref id="ref39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meyers</surname><given-names>RM</given-names></string-name>, <string-name><surname>Bryan</surname><given-names>JG</given-names></string-name>, <string-name><surname>McFarland</surname><given-names>JM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells</article-title>. <source>Nat Genet</source><year>2017</year>;<volume>49</volume>:<fpage>1779</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">29083409</pub-id></mixed-citation>
    </ref>
    <ref id="ref40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dempster</surname><given-names>JM</given-names></string-name>, <string-name><surname>Rossen</surname><given-names>J</given-names></string-name>, <string-name><surname>Kazachkova</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Extracting biological insights from the project Achilles Genome-scale CRISPR screens in cancer cell lines</article-title>. <source>bioRxiv</source><year>2019</year>;<fpage>720243</fpage>.</mixed-citation>
    </ref>
    <ref id="ref41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghandi</surname><given-names>M</given-names></string-name>, <string-name><surname>Huang</surname><given-names>FW</given-names></string-name>, <string-name><surname>Jané-Valbuena</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Next-generation characterization of the cancer cell line Encyclopedia</article-title>. <source>Nature</source><year>2019</year>;<volume>569</volume>:<fpage>503</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">31068700</pub-id></mixed-citation>
    </ref>
    <ref id="ref42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cheng</surname><given-names>X</given-names></string-name>, <string-name><surname>Yan</surname><given-names>J</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>eVITTA: a web-based visualization and inference toolbox for transcriptome analysis</article-title>. <source>Nucleic Acid Res</source><year>2021</year>;<volume>49</volume>:<fpage>W207</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">34019643</pub-id></mixed-citation>
    </ref>
    <ref id="ref43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoadley</surname><given-names>KA</given-names></string-name>, <string-name><surname>Yau</surname><given-names>C</given-names></string-name>, <string-name><surname>Hinoue</surname><given-names>T</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Cell-of-origin patterns dominate the molecular classification of 10 000 Tumors from 33 types of cancer</article-title>. <source>Cell</source><year>2018</year>;<volume>173</volume>:<fpage>291, e6</fpage>–<lpage>304</lpage>.<pub-id pub-id-type="pmid">29625048</pub-id></mixed-citation>
    </ref>
    <ref id="ref44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ellrott</surname><given-names>K</given-names></string-name>, <string-name><surname>Bailey</surname><given-names>MH</given-names></string-name>, <string-name><surname>Saksena</surname><given-names>G</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Scalable Open Science approach for mutation calling of tumor exomes using multiple genomic pipelines</article-title>. <source>Cell Syst</source><year>2018</year>;<volume>6</volume>:<fpage>271, e7</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">29596782</pub-id></mixed-citation>
    </ref>
    <ref id="ref45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Finak</surname><given-names>G</given-names></string-name>, <string-name><surname>McDavid</surname><given-names>A</given-names></string-name>, <string-name><surname>Yajima</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data</article-title>. <source>Genome Biol</source><year>2015</year>;<volume>16</volume>:<fpage>278</fpage>.<pub-id pub-id-type="pmid">26653891</pub-id></mixed-citation>
    </ref>
    <ref id="ref46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robinson</surname><given-names>MD</given-names></string-name>, <string-name><surname>McCarthy</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Smyth</surname><given-names>GK</given-names></string-name></person-group>. <article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title>. <source>Bioinformatics</source><year>2010</year>;<volume>26</volume>:<fpage>139</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">19910308</pub-id></mixed-citation>
    </ref>
    <ref id="ref47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname><given-names>W</given-names></string-name>, <string-name><surname>Laird</surname><given-names>PW</given-names></string-name>, <string-name><surname>Shen</surname><given-names>H</given-names></string-name></person-group>. <article-title>Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes</article-title>. <source>Nucleic Acid Res</source><year>2017</year>;<volume>45</volume>:<fpage>e22</fpage>.<pub-id pub-id-type="pmid">27924034</pub-id></mixed-citation>
    </ref>
    <ref id="ref48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heath</surname><given-names>AP</given-names></string-name>, <string-name><surname>Ferretti</surname><given-names>V</given-names></string-name>, <string-name><surname>Agrawal</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The NCI genomic data commons</article-title>. <source>Nat Genet</source><year>2021</year>;<volume>53</volume>:<fpage>257</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">33619384</pub-id></mixed-citation>
    </ref>
    <ref id="ref49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Colaprico</surname><given-names>A</given-names></string-name>, <string-name><surname>Silva</surname><given-names>TC</given-names></string-name>, <string-name><surname>Olsen</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data</article-title>. <source>Nucleic Acids Res</source><year>2016</year>;<volume>44</volume>:<fpage>e71</fpage>.<pub-id pub-id-type="pmid">26704973</pub-id></mixed-citation>
    </ref>
    <ref id="ref50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Silva</surname><given-names>TC</given-names></string-name>, <string-name><surname>Colaprico</surname><given-names>A</given-names></string-name>, <string-name><surname>Olsen</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>TCGA workflow: analyze cancer genomics and epigenomics data using Bioconductor packages</article-title>. <source>F1000Research</source><year>2016</year>;<volume>5</volume>:<fpage>1542</fpage>.<pub-id pub-id-type="pmid">28232861</pub-id></mixed-citation>
    </ref>
    <ref id="ref51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mounir</surname><given-names>M</given-names></string-name>, <string-name><surname>Lucchetta</surname><given-names>M</given-names></string-name>, <string-name><surname>Silva</surname><given-names>TC</given-names></string-name>, <etal>et al.</etal></person-group><article-title>New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx</article-title>. <source>PLoS Comput Biol</source><year>2019</year>;<volume>15</volume>:<fpage>e1006701</fpage>.<pub-id pub-id-type="pmid">30835723</pub-id></mixed-citation>
    </ref>
    <ref id="ref52">
      <label>52.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Carlson</surname><given-names>M</given-names></string-name></person-group>. <source><italic toggle="yes"><ext-link xlink:href="http://org.Hs.eg" ext-link-type="uri">org.Hs.eg</ext-link></italic><italic toggle="yes">.db: Genome wide annotation for Human</italic></source>.
<publisher-name>R package version 3.11.4</publisher-name>, <year>2020</year>.</mixed-citation>
    </ref>
    <ref id="ref53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corsello</surname><given-names>SM</given-names></string-name>, <string-name><surname>Nagari</surname><given-names>RT</given-names></string-name>, <string-name><surname>Spangler</surname><given-names>RD</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling</article-title>. <source>Nat Cancer</source><year>2020</year>;<volume>1</volume>:<fpage>235</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">32613204</pub-id></mixed-citation>
    </ref>
    <ref id="ref54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nusinow</surname><given-names>DP</given-names></string-name>, <string-name><surname>Szpyt</surname><given-names>J</given-names></string-name>, <string-name><surname>Ghandi</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Quantitative proteomics of the cancer cell line Encyclopedia</article-title>. <source>Cell</source><year>2020</year>;<volume>180</volume>:<fpage>387</fpage>–<lpage>402.e16</lpage>.<pub-id pub-id-type="pmid">31978347</pub-id></mixed-citation>
    </ref>
    <ref id="ref55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corsello</surname><given-names>SM</given-names></string-name>, <string-name><surname>Bittker</surname><given-names>JA</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The drug repurposing hub: a next-generation drug library and information resource</article-title>. <source>Nat Med</source><year>2017</year>;<volume>23</volume>:<fpage>405</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">28388612</pub-id></mixed-citation>
    </ref>
    <ref id="ref56">
      <label>56.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Therneau</surname><given-names>TM</given-names></string-name>, <string-name><surname>Grambsch</surname><given-names>PM</given-names></string-name></person-group>. <source>Modeling Survival Data. Extending the Cox Model</source>. Springer, Berlin, <year>2000</year>.</mixed-citation>
    </ref>
    <ref id="ref57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lausen</surname><given-names>B</given-names></string-name>, <string-name><surname>Schumacher</surname><given-names>M</given-names></string-name></person-group>. <article-title>Maximally selected rank statistics</article-title>. <source>Biometrics</source><year>1992</year>;<volume>48</volume>:<fpage>73</fpage>–<lpage>85</lpage>.</mixed-citation>
    </ref>
    <ref id="ref58">
      <label>58.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name><surname>Lausen</surname><given-names>B</given-names></string-name>, <string-name><surname>Sauerbrei</surname><given-names>W</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Dangers of using “optimal” cutpoints in the evaluation of prognostic factors</article-title>. <source>JNCI J Natl Cancer Inst</source><year>1994</year>;<volume>86</volume>:<fpage>829</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">8182763</pub-id></mixed-citation>
    </ref>
    <ref id="ref59">
      <label>59.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Perkins</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Schisterman</surname><given-names>EF</given-names></string-name></person-group>. <article-title>The inconsistency of “optimal” cut-points using two ROC based criteria</article-title>. <source>Am J Epidemiol</source><year>2006</year>;<volume>163</volume>:<fpage>670</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">16410346</pub-id></mixed-citation>
    </ref>
    <ref id="ref60">
      <label>60.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Camp</surname><given-names>RL</given-names></string-name>, <string-name><surname>Dolled-Filhart</surname><given-names>M</given-names></string-name>, <string-name><surname>Rimm</surname><given-names>DL</given-names></string-name></person-group>. <article-title>X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization</article-title>. <source>Clin Cancer Res Off J Am Assoc Cancer Res</source><year>2004</year>;<volume>10</volume>:<fpage>7252</fpage>–<lpage>9</lpage>.</mixed-citation>
    </ref>
    <ref id="ref61">
      <label>61.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Budczies</surname><given-names>J</given-names></string-name>, <string-name><surname>Klauschen</surname><given-names>F</given-names></string-name>, <string-name><surname>Sinn</surname><given-names>BV</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker Cutoff optimization</article-title>. <source>PLoS One</source><year>2012</year>;<volume>7</volume>:<fpage>e51862</fpage>.<pub-id pub-id-type="pmid">23251644</pub-id></mixed-citation>
    </ref>
    <ref id="ref62">
      <label>62.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hilsenbeck</surname><given-names>SG</given-names></string-name>, <string-name><surname>Clark</surname><given-names>GM</given-names></string-name></person-group>. <article-title>Practical <italic toggle="yes">P</italic>-value adjustment for optimally selected cutpoints</article-title>. <source>Stat Med</source><year>1996</year>;<volume>15</volume>:<fpage>103</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">8614741</pub-id></mixed-citation>
    </ref>
    <ref id="ref63">
      <label>63.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>R Core Team. R</collab></person-group><italic toggle="yes">:</italic><source>A Language and Environment for Statistical Computing</source>.
<publisher-name>R Foundation for Statistical Computing</publisher-name>, <publisher-loc>Vienna, Austria</publisher-loc>. URL <ext-link xlink:href="https://www.R-project.org/" ext-link-type="uri">https://www.R-project.org/</ext-link>. <year>2020</year>.</mixed-citation>
    </ref>
    <ref id="ref64">
      <label>64.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kassambara</surname><given-names>A</given-names></string-name>, <string-name><surname>Kosinski</surname><given-names>M</given-names></string-name>, <string-name><surname>Biecek</surname><given-names>P</given-names></string-name></person-group>. <article-title>Survminer: drawing survival curves using ‘ggplot2’</article-title>. <source>R package version 049</source><year>2021</year>. <ext-link xlink:href="https://rpkgs.datanovia.com/survminer/index.html" ext-link-type="uri">https://rpkgs.datanovia.com/survminer/index.html</ext-link>.</mixed-citation>
    </ref>
    <ref id="ref65">
      <label>65.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wickham</surname><given-names>H</given-names></string-name>, <string-name><surname>Averick</surname><given-names>M</given-names></string-name>, <string-name><surname>Bryan</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Welcome to the Tidyverse</article-title>. <source>J Open Source Softw</source><year>2019</year>;<volume>4</volume>:<fpage>1686</fpage>.</mixed-citation>
    </ref>
    <ref id="ref66">
      <label>66.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Joly</surname><given-names>JH</given-names></string-name>, <string-name><surname>Delfarah</surname><given-names>A</given-names></string-name>, <string-name><surname>Phung</surname><given-names>PS</given-names></string-name>, <etal>et al.</etal></person-group><article-title>A synthetic lethal drug combination mimics glucose deprivation–induced cancer cell death in the presence of glucose</article-title>. <source>J Biol Chem</source><year>2020</year>;<volume>295</volume>:<fpage>1350</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">31914417</pub-id></mixed-citation>
    </ref>
    <ref id="ref67">
      <label>67.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jaramillo</surname><given-names>MC</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>DD</given-names></string-name></person-group>. <article-title>The emerging role of the Nrf2–Keap1 signaling pathway in cancer</article-title>. <source>Genes Dev</source><year>2013</year>;<volume>27</volume>:<fpage>2179</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">24142871</pub-id></mixed-citation>
    </ref>
    <ref id="ref68">
      <label>68.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Collisson</surname><given-names>EA</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>JD</given-names></string-name>, <string-name><surname>Brooks</surname><given-names>AN</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Comprehensive molecular profiling of lung adenocarcinoma</article-title>. <source>Nature</source><year>2014</year>;<volume>511</volume>:<fpage>543</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">25079552</pub-id></mixed-citation>
    </ref>
    <ref id="ref69">
      <label>69.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><prefix>de la</prefix><surname>Vega</surname><given-names>MR</given-names></string-name>, <string-name><surname>Chapman</surname><given-names>E</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>DD</given-names></string-name></person-group>. <article-title>NRF2 and the hallmarks of cancer</article-title>. <source>Cancer Cell</source><year>2018</year>;<volume>34</volume>:<fpage>21</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">29731393</pub-id></mixed-citation>
    </ref>
    <ref id="ref70">
      <label>70.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singh</surname><given-names>A</given-names></string-name>, <string-name><surname>Misra</surname><given-names>V</given-names></string-name>, <string-name><surname>Thimmulappa</surname><given-names>RK</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Dysfunctional KEAP1–NRF2 interaction in non-small-cell lung cancer</article-title>. <source>PLoS Med</source><year>2006</year>;<volume>3</volume>:<fpage>e420</fpage>.<pub-id pub-id-type="pmid">17020408</pub-id></mixed-citation>
    </ref>
    <ref id="ref71">
      <label>71.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thor</surname><given-names>H</given-names></string-name>, <string-name><surname>Smith</surname><given-names>MT</given-names></string-name>, <string-name><surname>Hartzell</surname><given-names>P</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells</article-title>. <source>J Biol Chem</source><year>1982</year>;<volume>257</volume>:<fpage>12419</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">6181068</pub-id></mixed-citation>
    </ref>
    <ref id="ref72">
      <label>72.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ohta</surname><given-names>T</given-names></string-name>, <string-name><surname>Iijima</surname><given-names>K</given-names></string-name>, <string-name><surname>Miyamoto</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth</article-title>. <source>Cancer Res</source><year>2008</year>;<volume>68</volume>:<fpage>1303</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">18316592</pub-id></mixed-citation>
    </ref>
    <ref id="ref73">
      <label>73.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>X-J</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Z</given-names></string-name>, <string-name><surname>Villeneuve</surname><given-names>NF</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2</article-title>. <source>Carcinogenesis</source><year>2008</year>;<volume>29</volume>:<fpage>1235</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">18413364</pub-id></mixed-citation>
    </ref>
    <ref id="ref74">
      <label>74.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gong</surname><given-names>M</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ye</surname><given-names>X</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation</article-title>. <source>Cell Commun Signal CCS</source><year>2020</year>;<volume>18</volume>:<fpage>98</fpage>.<pub-id pub-id-type="pmid">32576270</pub-id></mixed-citation>
    </ref>
    <ref id="ref75">
      <label>75.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yuan</surname><given-names>J</given-names></string-name>, <string-name><surname>Hu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Mahal</surname><given-names>BA</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Integrated analysis of genetic ancestry and genomic alterations across cancers</article-title>. <source>Cancer Cell</source><year>2018</year>;<volume>34</volume>:<fpage>549</fpage>–<lpage>560.e9</lpage>.<pub-id pub-id-type="pmid">30300578</pub-id></mixed-citation>
    </ref>
    <ref id="ref76">
      <label>76.</label>
      <mixed-citation publication-type="journal"><article-title>International network of cancer genome projects</article-title>. <source>Nature</source><year>2010</year>;<volume>464</volume>:<fpage>993</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">20393554</pub-id></mixed-citation>
    </ref>
    <ref id="ref77">
      <label>77.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thorsson</surname><given-names>V</given-names></string-name>, <string-name><surname>Gibbs</surname><given-names>DL</given-names></string-name>, <string-name><surname>Brown</surname><given-names>SD</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The immune landscape of cancer</article-title>. <source>Immunity</source><year>2018</year>;<volume>48</volume>:<fpage>812</fpage>–<lpage>830.e14</lpage>.<pub-id pub-id-type="pmid">29628290</pub-id></mixed-citation>
    </ref>
    <ref id="ref78">
      <label>78.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A</given-names></string-name>, <string-name><surname>Narayan</surname><given-names>R</given-names></string-name>, <string-name><surname>Corsello</surname><given-names>SM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>A next generation connectivity map: L1000 platform and the first 1 000 000 profiles</article-title>. <source>Cell</source><year>2017</year>;<volume>171</volume>:<fpage>1437</fpage>–<lpage>1452.e17</lpage>.<pub-id pub-id-type="pmid">29195078</pub-id></mixed-citation>
    </ref>
    <ref id="ref79">
      <label>79.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lamb</surname><given-names>J</given-names></string-name>, <string-name><surname>Crawford</surname><given-names>ED</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease</article-title>. <source>Science</source><year>2006</year>;<volume>313</volume>:<fpage>1929</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">17008526</pub-id></mixed-citation>
    </ref>
    <ref id="ref80">
      <label>80.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>JW</given-names></string-name>, <string-name><surname>Williams</surname><given-names>M</given-names></string-name></person-group>. <part-title>Repurposing routine imaging for cancer biomarker discovery using machine learning</part-title>. In: <source><italic toggle="yes">Handbook of Artificial Intelligence in Healthcare</italic>, <italic toggle="yes">Vol 1 - Advances and Applications</italic></source>, Springer International Publishing <year>2022</year>, <fpage>153</fpage>–<lpage>76</lpage>.</mixed-citation>
    </ref>
    <ref id="ref81">
      <label>81.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gibbons</surname><given-names>JA</given-names></string-name>, <string-name><prefix>de</prefix><surname>Vries</surname><given-names>M</given-names></string-name>, <string-name><surname>Krauwinkel</surname><given-names>W</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Pharmacokinetic drug interaction studies with enzalutamide</article-title>. <source>Clin Pharmacokinet</source><year>2015</year>;<volume>54</volume>:<fpage>1057</fpage>–<lpage>69</lpage>.<pub-id pub-id-type="pmid">25929560</pub-id></mixed-citation>
    </ref>
    <ref id="ref82">
      <label>82.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Gu</surname><given-names>L</given-names></string-name>, <string-name><surname>Eils</surname><given-names>R</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Circlize implements and enhances circular visualization in R</article-title>. <source>Bioinformatics</source><year>2014</year>;<volume>30</volume>:<fpage>2811</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="pmid">24930139</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
